title: Stereotactic body radiation therapy for centrally-located lung tumors.
abstract: The application of high-dose irradiation to centrally-located lung tumors is generally considered to be of high risk in causing bronchial injury. The aim of the present retrospective study was to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with centrally-located lung tumors. In total, 28 patients who underwent SBRT for lung tumors within 2 cm of a major bronchus were retrospectively analyzed. The median total dose prescribed was 45 Gy (range, 36.3-52.5 Gy), the median fraction was 12 (range, 10-15) and the median dose per fraction was 3.6 Gy (range, 3-5 Gy). The median follow-up period for the surviving patients was 14 months (range, 10-41 months). The local control rate of SBRT was 100%, with a complete response (CR) rate of 32.1% (9/28); a partial response (PR) rate of 50% (14/28) and a stable disease (SD) rate of 17.9% (5/28). In total, 15 patients survived and 13 patients succumbed; 11 patients succumbed to tumor progression, one to congestive heart failure and one to a brain hemorrhage. The main side-effects included grade 2 esophagitis (17.9%; 5/28) atelectasis (10.7%; 3/28) and grade 2 late radiation pneumonitis (7.1%; 2/28). Severe late toxicity (≥ grade 3) was not observed in any patient. SBRT is an effective and safe therapy for centrally-located lung tumors.
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Ge
authors.initials: G
authors.lastname: Shen
authors.affiliation: Army Radiation Cancer Center and Department of Radiation Oncology, Air Force General Hospital, Beijing 100036, P.R. China.
authors.forename: Ying-Jie
authors.initials: YJ
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Wen-Jiang
authors.initials: WJ
authors.lastname: Shen
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Zhen-Shan
authors.initials: ZS
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Jun-Liang
authors.initials: JL
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Hong-Guo
authors.initials: HG
authors.lastname: Sheng
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: DA-Peng
authors.initials: DP
authors.lastname: Dong
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Gang
authors.initials: G
authors.lastname: Yang
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Qin-Wen
authors.initials: QW
authors.lastname: Wang
authors.affiliation: Biomedical Engineering Center, Beijing University of Technology, Beijing 100022, P.R. China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Zeng
keywords: centrally-located; lung tumor; stereotactic body radiation therapy